Ardelyx (ARDX) AI Stock Analysis

Compare

1,625 Followers

ARDX Dividends

Top Page

Ardelyx

(NASDAQ:ARDX)

56Neutral

Ardelyx's overall score reflects strong revenue growth and strategic product successes, particularly with IBSRELA and XPHOZAH. However, ongoing net losses, increased leverage, and technical weakness in stock trends present challenges. The positive outlook from the earnings call partially offsets these concerns, but financial sustainability remains a key focus.

Positive Factors

Financial Performance

4Q24 was ARDX's first product-driven profitable quarter, and minimal cash impact from operations is expected through FY25.

Market Opportunities

Ibsrela and Xphozah continue to build momentum in large market opportunities with no second-line competition, supporting a clear path to returned profitability.

Negative Factors

Investor Sentiment

A significant overhang on investor sentiment and the stock is expected until there is a resolution to the uncertainty around Medicare patient access for XPHOZAH.

Medicare Coverage

XPHOZAH's near-term and long-term outlook remains uncertain since it became unavailable under Medicare Part D.

Stock Rating

Analysts anticipate a substantial drop in XPHOZAH sales due to its inclusion in the Medicare bundle, leading to a downgrade of the stock rating.

Ardelyx (ARDX) vs. S&P 500 (SPY)

Market Cap

$1.09B

Dividend YieldN/A

Average Volume (3M)4.85M

Price to Earnings (P/E)―

Beta (1Y)0.99

Revenue Growth168.06%

EPS Growth44.66%

CountryUS

Employees395

SectorHealthcare

Sector Strength64

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.17

Shares Outstanding238,356,220

10 Day Avg. Volume5,940,325

30 Day Avg. Volume4,852,080

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)3.67

Price to Cash Flow (P/CF)31.20

P/FCF Ratio31.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$11.31

Price Target Upside135.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Ardelyx Business Overview & Revenue Model

Company DescriptionArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

How the Company Makes MoneyArdelyx generates revenue primarily through the commercialization of its proprietary product, tenapanor. The company earns money by selling this medication to healthcare providers and pharmacies, which distribute it to patients. Additionally, Ardelyx may engage in licensing agreements and strategic partnerships to expand its product's reach and enhance its market penetration. Such collaborations can include upfront payments, milestone payments, and royalties based on sales, contributing to the company's revenue streams. Ardelyx's revenue model is heavily reliant on the successful adoption and market acceptance of tenapanor, as well as its ability to establish and maintain strong partnerships within the healthcare and pharmaceutical sectors.

Ardelyx Financial Statement Overview

Summary

Ardelyx shows impressive revenue growth, but profitability remains an issue with ongoing net losses and negative margins. The balance sheet is stable but increasingly leveraged, and cash flow management poses challenges, relying on external financing.

Income Statement

Neutral

Ardelyx has shown significant revenue growth, increasing from $52.16M in 2022 to $124.46M in 2023, and reaching $333.62M in 2024. However, the company remains unprofitable with a negative net profit margin, as net losses continue, albeit reducing from previous years. The negative EBIT and EBITDA margins indicate ongoing challenges in covering operating costs, impacting profitability.

Balance Sheet

Neutral

The balance sheet shows a moderate debt-to-equity ratio, with total debt increasing but equity also rising. The company's equity ratio is weakening, indicating a potential shift towards more leveraged operations. Despite this, the return on equity remains negative due to consistent net losses. The company's financial position is stable but dependent on managing leverage carefully.

Cash Flow

Neutral

Despite improvements in operating cash flow, Ardelyx continues to experience negative free cash flow, reflecting ongoing challenges in generating sufficient cash from operations. The operating cash flow to net income ratio indicates some improvement in cash generation relative to net losses, but the need for financing activities to support operations persists.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
333.62M	124.46M	52.16M	10.10M	7.57M
	Gross Profit
283.06M	106.66M	48.04M	9.10M	7.43M
	EBIT
-27.95M	-63.28M	-63.76M	-154.35M	-90.78M
	EBITDA
-16.71M	-55.35M	-60.98M	-150.85M	-85.24M
	Net Income Common Stockholders
-39.14M	-66.07M	-67.21M	-158.16M	-94.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
250.10M	184.30M	123.91M	116.69M	186.48M
	Total Assets
435.75M	297.58M	190.07M	149.91M	201.56M
	Total Debt
153.44M	55.98M	36.46M	45.50M	53.32M
	Net Debt
88.51M	34.51M	-59.68M	-26.92M	-37.71M
	Total Liabilities
262.46M	130.76M	91.74M	67.30M	75.45M
	Stockholders Equity
173.29M	166.82M	98.33M	82.62M	126.11M
Cash Flow		Free Cash Flow
-45.82M	-90.06M	-70.10M	-154.42M	-81.76M
	Operating Cash Flow
-44.81M	-89.72M	-70.04M	-152.55M	-81.44M
	Investing Cash Flow
-18.32M	-131.25M	18.41M	50.95M	-31.44M
	Financing Cash Flow
106.59M	146.29M	75.34M	83.00M	22.78M

Ardelyx Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price4.81

Price Trends

50DMA

5.15

Negative

100DMA

5.21

Negative

200DMA

5.52

Negative

Market Momentum

MACD

-0.15

Negative

RSI

49.69

Neutral

STOCH

87.26

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Neutral. The current price of 4.81 is above the 20-day moving average (MA) of 4.71, below the 50-day MA of 5.15, and below the 200-day MA of 5.52, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 49.69 is Neutral, neither overbought nor oversold. The STOCH value of 87.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARDX.

Ardelyx Risk Analysis

Ardelyx disclosed 52 risk factors in its most recent earnings report. Ardelyx reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Ardelyx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	68 Neutral	$1.05B	198.45	1.52%	―	33.97%	―
MDXG	64 Neutral	$965.25M	23.02	25.01%	―	8.52%	-32.91%
ARDX	56 Neutral	$1.09B	―	-23.01%	―	168.06%	44.66%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
OCUL	50 Neutral	$1.21B	―	-95.21%	―	9.03%	-25.00%
CLDX	47 Neutral	$1.26B	―	-26.84%	―	1.99%	15.95%
LQDA	45 Neutral	$1.13B	―	-209.35%	―	-19.97%	-37.22%

* Healthcare Sector Average

Performance Comparison

ARDX

Ardelyx

4.56

-1.83

-28.64%

CLDX

Celldex

19.39

-18.38

-48.66%

MDXG

MiMedx Group

6.68

0.17

2.61%

OCUL

Ocular Therapeutix

7.91

2.91

58.20%

AUPH

Aurinia Pharmaceuticals

7.89

2.80

55.01%

LQDA

Liquidia Technologies

13.49

0.54

4.17%

Ardelyx Earnings Call Summary

Earnings Call Date: Feb 20, 2025 | % Change Since: -24.37% | Next Earnings Date: May 1, 2025

Earnings Call Sentiment Positive

Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.

Highlights

IBSRELA Growth

IBSRELA reported a more than 32% growth quarter-over-quarter from Q3 of the same fiscal year, demonstrating strong demand and successful sales-force expansion.

XPHOZAH Launch Success

XPHOZAH achieved $57.2 million in net product sales revenue for the fourth quarter, marking an 11% increase over Q3, highlighting its importance in treating hyperphosphatemia.

Strong Financial Position

Ardelyx ended the fiscal year with $250 million in cash, cash equivalents, and short-term investments, an increase from $184.3 million at the end of 2023.

Year-Over-Year Revenue Growth

The company reported total revenues of $333.6 million for 2024, compared to $124.5 million in the prior year, driven by IBSRELA and XPHOZAH sales.

Positive Net Income

Ardelyx reported a net income of approximately $4.6 million for the fourth quarter, compared to a net loss of $28.8 million in the same period of the prior year.

Lowlights

Medicare Part D Coverage Loss for XPHOZAH

XPHOZAH is no longer covered by Medicare Part D, which may affect access for some patients despite efforts to maintain availability through other programs.

Increased SG&A Expenses

Selling, general, and administrative expenses rose to $76.1 million for Q4 2024, up from $47.8 million in the prior year, reflecting increased commercial activities.

Uncertain First Quarter for XPHOZAH

The company could not provide a detailed outlook for XPHOZAH's performance in the first quarter of 2025 due to ongoing market adjustments.

Company Guidance

In the Ardelyx Fourth Quarter and Fiscal Year 2024 earnings call, the company provided guidance on its financial expectations and strategic priorities for 2025 and beyond. The company reported total revenues of $333.6 million for 2024, a significant increase from $124.5 million in the previous year, driven by the growth of IBSRELA and the launch of XPHOZAH. IBSRELA achieved a 32% quarter-over-quarter growth rate in Q4 and is projected to generate between $240 million and $250 million in net product sales revenue in 2025, with a long-term goal of exceeding $1 billion in annual sales prior to patent expiry. XPHOZAH, which achieved $160.9 million in annual sales in 2024, is projected to reach $750 million in annual net sales before patent expiry. The company ended the year with a strong cash position of $250.1 million, bolstered by $49.7 million in proceeds from a term loan agreement, and plans to strategically invest in expanding its commercial and patient services teams to drive continued growth.

Ardelyx Corporate Events

Executive/Board Changes

Ardelyx Appoints Joseph Reilly as Principal Accounting Officer

Positive

Nov 18, 2024

The company has announced the appointment of Joseph Reilly as the new Principal Accounting Officer, effective November 15, 2024, succeeding Robert Felsch, who will transition to a senior financial advisor role. With a robust background in finance from Bristol Myers Squibb and Ernst & Young, Reilly is expected to bring extensive expertise to his new position. This leadership change signals the company’s commitment to maintaining financial stability and ensuring seamless transitions within its executive team.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.